The Foundation for Sarcoidosis Research is urging adults with sarcoidosis to participate in a new study that will…
Articles by Joana Carvalho, PhD
As part of a new agreement with AdVita Lifescience, Relief Therapeutics will acquire the intellectual rights for the specifications…
The Foundation for Sarcoidosis Research (FSR) is launching a series of mindfulness and meditation workshops — all as…
Women with sarcoidosis are more likely to die in hospital from heart complications and also to experience sudden…
ATYR1923, aTyr Pharma’s lead investigational therapy for pulmonary sarcoidosis, is safe and well-tolerated, according to…
The soluble interleukin 2 receptor (sIL-2R) is more sensitive and specific than the angiotensin-converting enzyme (ACE), one of the most…
Depression and anxiety may worsen the quality of life and lung function of patients with pulmonary sarcoidosis,…
The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough therapy to Ofev (…
People with hepatitis C who develop sarcoidosis may be safely treated with adalimumab, marketed by Abbvie as …
Patients with advanced sarcoidosis have limited daily life physical activity, mostly because their lungs’ maximal oxygen uptake is reduced,…